CTGF is a therapeutic target for metastatic melanoma

Oncogene. 2014 Feb 27;33(9):1093-100. doi: 10.1038/onc.2013.47. Epub 2013 Feb 25.

Abstract

Metastatic melanoma remains a devastating disease with a 5-year survival rate of less than five percent. Despite recent advances in targeted therapies for melanoma, only a small percentage of melanoma patients experience durable remissions. Therefore, it is critical to identify new therapies for the treatment of advanced melanoma. Here, we define connective tissue growth factor (CTGF) as a therapeutic target for metastatic melanoma. Clinically, CTGF expression correlates with tumor progression and is strongly induced by hypoxia through HIF-1 and HIF-2-dependent mechanisms. Genetic inhibition of CTGF in human melanoma cells is sufficient to significantly reduce orthotopic tumor growth, as well as metastatic tumor growth in the lung of severe combined immunodeficient (SCID) mice. Mechanistically, inhibition of CTGF decreased invasion and migration associated with reduced matrix metalloproteinase-9 expression. Most importantly, the anti-CTGF antibody, FG-3019, had a profound inhibitory effect on the progression of established metastatic melanoma. These results offer the first preclinical validation of anti-CTGF therapy for the treatment of advanced melanoma and underscore the importance of tumor hypoxia in melanoma progression.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal, Humanized
  • Basic Helix-Loop-Helix Transcription Factors / genetics
  • Cell Line, Tumor
  • Connective Tissue Growth Factor / antagonists & inhibitors*
  • Connective Tissue Growth Factor / genetics*
  • Disease Progression
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Hypoxia / genetics
  • Hypoxia-Inducible Factor 1 / genetics
  • Matrix Metalloproteinase 9 / genetics
  • Melanoma / drug therapy*
  • Melanoma / genetics*
  • Melanoma / pathology
  • Mice
  • Mice, SCID

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Basic Helix-Loop-Helix Transcription Factors
  • CCN2 protein, human
  • Hypoxia-Inducible Factor 1
  • Connective Tissue Growth Factor
  • endothelial PAS domain-containing protein 1
  • Matrix Metalloproteinase 9
  • pamrevlumab